Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

616
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
616

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A High-Quality Endoscopic Image Dataset with Annotated Recurrent Laryngeal Nerve for AI-Assisted Thyroid Surgery.

Scientific data·2026
Same author

Pancreatic cancer cells escape T/NK cell immune surveillance through the expressional separation of CD58.

Journal for immunotherapy of cancer·2025
Same author

Molecular profiling reveals the malignant potential in solid pseudopapillary neoplasms of the pancreas.

Cancer letters·2025
Same author

Double-Cavity Fabry-Perot Interferometer Sensor Based on Polymer-Filled Hollow Core Fiber for Simultaneous Measurement of Temperature and Gas Pressure.

Sensors (Basel, Switzerland)·2025
Same author

Epigenetic modification and tumor immunity: Unraveling the interplay with the tumor microenvironment and its therapeutic vulnerability and implications.

Cancer letters·2025
Same author

Chimeric antigen receptor macrophages targeting c-MET(CAR-M-c-MET) inhibit pancreatic cancer progression and improve cytotoxic chemotherapeutic efficacy.

Molecular cancer·2024

Related Experiment Video

Updated: Aug 11, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.2K

Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.

Qiaofei Liu1, Jiayi Li1, Huaijin Zheng1

  • 1Department of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, No.1 Shuai Fu Yuan, Dongcheng District, Beijing, 100730, China.

Molecular Cancer
|February 8, 2023
PubMed
Summary
This summary is machine-generated.

New adoptive cell therapies like TCR-T, CAR-NK, and CAR-M show promise for solid tumors where CAR-T and immune checkpoint blockade therapies fall short due to tumor microenvironment challenges.

Keywords:
Adoptive cell therapyChimeric antigen receptorImmune checkpointMacrophageNatural killer cellTCR

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

990

Related Experiment Videos

Last Updated: Aug 11, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.2K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

21.5K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

990

Area of Science:

  • Immunotherapy
  • Oncology
  • Cellular Therapy

Background:

  • Immune checkpoint blockade and CAR-T therapy are key immunotherapies but have limited efficacy in solid tumors.
  • Solid tumor treatment failures are linked to low tumor antigenicity, poor T cell infiltration, and immunosuppressive microenvironments.

Purpose of the Study:

  • To review the evolution of adoptive cell therapies over 40 years.
  • To focus on advances in TCR-T, CAR-NK, and CAR-M therapies for solid neoplasms.
  • To discuss the clinical potential of these novel cell therapies.

Main Methods:

  • Literature review of adoptive cell therapy evolution.
  • Analysis of recent advancements in TCR-T, CAR-NK, and CAR-M therapies.
  • Discussion of challenges and opportunities in solid tumor treatment.

Main Results:

  • CAR-T and immune checkpoint blockade face significant challenges in solid neoplasms.
  • Emerging therapies like TCR-T, CAR-NK, and CAR-M offer potential advantages.
  • These novel therapies aim to overcome limitations of previous immunotherapeutic approaches.

Conclusions:

  • TCR-T, CAR-NK, and CAR-M therapies represent the next generation of adoptive cell therapies for solid tumors.
  • These approaches hold promise for improving patient outcomes in challenging malignancies.
  • Further research and clinical trials are essential to realize their full therapeutic potential.